The test uses isothermal nucleic acid amplification to return results in 20 minutes at the point of care, and demonstrated 98 percent agreement with PCR testing.
Demand for SARS-CoV-2 testing sent lab revenues soaring while changes in patterns of patient care and regulations that could have impacts for years to come.
At an AMP virtual meeting workshop, a Mayo Clinic lab director offered advice on what diseases to include, how to handle VUSs, and other considerations for ECS.
Sciex has discontinued the Topaz platform three years after its launch while Thermo Fisher aims to drive adoption of its Cascadion following a recent US launch.
The firm expects to launch a tissue-based immunohistochemistry version of the test, which detects QSOX1, in mid-2021, followed by a dipstick plasma-based assay by early 2022.
